Analysts expect Alx Oncology Holdings Inc to report revenue of 0.00 for Q2 26, against a range of 0.00 to 0.00. The most recent reported quarter, Q1 26, came in at 0.00.
| Metric | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - |
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analysts expect Alx Oncology Holdings Inc to report earnings per share of -0.15 for Q2 26, against a range of -0.16 to -0.14. The most recent reported quarter, Q1 26, came in at -0.17, a 15.0% beat against the -0.20 consensus.
| Metric | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.76 | -0.58 | -0.55 | -0.58 | -0.49 | -0.41 | -0.42 | -0.17 | - | - | - | - | - | - | - | - | |||||||||||
| High Estimate | -0.73 | -0.70 | -0.63 | -0.42 | -0.36 | -0.33 | -0.34 | -0.18 | -0.14 | -0.14 | -0.15 | -0.15 | -0.06 | -0.03 | -0.06 | -0.20 | |||||||||||
| Low Estimate | -0.83 | -0.78 | -0.75 | -0.46 | -0.44 | -0.39 | -0.36 | -0.22 | -0.16 | -0.18 | -0.17 | -0.17 | -0.06 | -0.03 | -0.06 | -0.22 | |||||||||||
| Consensus Estimate | -0.78 | -0.74 | -0.69 | -0.44 | -0.40 | -0.36 | -0.35 | -0.20 | -0.15 | -0.16 | -0.16 | -0.16 | -0.06 | -0.03 | -0.06 | -0.21 |